Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. Find out why DMRA stock is a ...
Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, ...
WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the first ...
DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European ...
RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:30 AM EDTCompany ParticipantsSteven Stein - Executive ...
Key Points Interested in Incyte Corporation? Here are five stocks we like better. Incyte's CEO says the company's post-Jakafi ...
The IMpactMF trial’s interim analysis in the second half of 2026 is presented as a potential catalyst with implications for both product expansion and physician awareness. Expectations for back-half ...
Scientists wanted to know why the chatter of Alston’s singing mice sounds so much like human conversation. What they found might change how we study both species. By Annie Roth In the balmy cloud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results